2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase

British Journal of Pharmacology

Volumn 160, Issue 7, 2010, Pages 1677-1689

  Chang, Wei Ling ^a   Chang, Chih Shiang ^b   Chiang, Po Cheng ^a   Ho, Yunn Fang ^a   Liu, Ju Fang ^b   Chang, Kai Wei ^b   Guh, Jih Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

cell cycle progression; intrinsic apoptotic pathway; JNK; microtubule; prostate cancer

Indexed keywords

2 PHENYL 5 (PYRROLIDIN 1 YL) 1 (3,4,5 TRIMETHOXYBENZYL) 1H BENZIMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CASPASE 3; CASPASE 9; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; GLYCOPROTEIN P; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; THREONINE; TUBULIN; TYROSINE; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME SUBSTRATE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROTUBULE; MITOCHONDRION; MITOSIS; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANISOLES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICROTUBULES; MITOTIC SPINDLE APPARATUS; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; SUBSTRATE SPECIFICITY; TUBULIN;

EID: 77954342540     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00832.x     Document Type: Article

References (38)

1. Bhalla KN (2003). Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075 9086.
2. Bode AM, Dong Z (2007). The functional contrariety of JNK. Mol Carcinog 46:591 598.
3. Brozovic A, Osmak M (2007). Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251:1 16.
4. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ et al. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100 104.
5. Carboni S, Boschert U, Gaillard P, Gotteland JP, Gillon JY, Vitte PA (2008). AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br J Pharmacol 153:157 163.
6. Chang EJ, Ha J, Huang H, Kim HJ, Woo JH, Lee Y et al. (2008). The JNK-dependent CaMK pathway restrains the reversion of committed cells during osteoclast differentiation. J Cell Sci 121:2555 2564.
7. Ciallella JR, Saporito M, Lund S, Leist M, Hasseldam H, McGann N et al. (2005). CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice. Eur J Pharmacol 515:179 187.
8. Condorelli F, Salomoni P, Cotteret S, Cesi V, Srinivasula SM, Alnemri ES et al. (2001). Caspase cleavage enhances the apoptosis-inducing effects of BAD. Mol Cell Biol 21:3025 3036.
9. Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, Bonnet ML et al. (2006). BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 134:171 179.
10. Critchley J, Addiss D, Gamble C, Garner P, Gelband H, Ejere H et al. (2005). Albendazole for lymphatic filariasis. Cochrane Database Syst Rev 19:CD003753.
11. Farley K, Mett H, McGlynn E, Murray B, Lydon NB (1992). Development of solid-phase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity. Anal Biochem 203:151 157.
12. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623 18632.
13. Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC et al. (2007). STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells. J Pharmacol Exp Ther 321:288 297.
14. Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM (1998). Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 53:467 474.
15. Haldar S, Jena N, Croce CM (1995). Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507 4511.
16. Kolomeichuk SN, Terrano DT, Lyle CS, Sabapathy K, Chambers TC (2008). Distinct signaling pathways of microtubule inhibitors - vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively. FEBS J 275:1889 1899.
17. Kutuk O, Letai A (2008). Regulation of Bcl-2 family proteins by posttranslational modifications. Curr Mol Med 8:102 118.
18. van Leuken R, Clijsters L, Wolthuis R (2008). To cell cycle, swing the APC/C. Biochim Biophys Acta 1786:49 59.
19. Li M, Feurino LW, Li F, Wang H, Zhai Q, Fisher WE et al. (2007). Thymosinalpha1 stimulates cell proliferation by activating ERK1/2, JNK, and increasing cytokine secretion in human pancreatic cancer cells. Cancer Lett 248:58 67.
20. Marinho J, Pedro M, Pinto DC, Silva AM, Cavaleiro JA, Sunkel CE et al. (2008). 4′-Methoxy-2-styrylchromone a novel microtubule-stabilizing antimitotic agent. Biochem Pharmacol 75:826 835.
21. Metzinger DS, Taylor DD, Gercel-Taylor C (2006). Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Lett 236:302 308.
22. Mizuchi D, Kurosu T, Kida A, Jin ZH, Jin A, Arai A et al. (2005). BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. Biochem Biophys Res Commun 326:645 651.
23. Moon DO, Kim MO, Kang SH, Lee KJ, Heo MS, Choi KS et al. (2008). Induction of G2/M arrest, endoreduplication, and apoptosis by actin depolymerization agent pextenotoxin-2 in human leukemia cells, involving activation of ERK and JNK. Biochem Pharmacol 76:312 321.
24. Muscarella DE, Bloom SE (2008). The contribution of c-Jun N-terminal kinase activation and subsequent Bcl-2 phosphorylation to apoptosis induction in human B-cells is dependent on the mode of action of specific stresses. Toxicol Appl Pharmacol 228:93 104.
25. Nagata K, Puls A, Futter C, Aspenstrom P, Schaefer E, Nakata T et al. (1998). The MAP kinase kinase kinase MLK2 co-localizes with activated JNK along microtubules and associates with kinesin superfamily motor KIF3. EMBO J 17:149 158.
26. Nishina H, Wada T, Katada T (2004). Physiological roles of SAPK/JNK signaling pathway. J Biochem 136:123 126.
27. Pellegrini F, Budman DR (2005). Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23:264 273.
28. Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T (1998). Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 58:3331 3338.
29. Reed JC, Zha H, Aime-Sempe C, Takayama S, Wang HG (1996). Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv Exp Med Biol 406:99 112.
30. Stone AA, Chambers TC (2000). Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 254:110 119.
31. Sun SC, Xiong B, Lu SS, Sun QY (2008). MEK1/2 is a critical regulator of microtubule assembly and spindle organization during rat oocyte meiotic maturation. Mol Reprod Dev 75:1542 1548.
32. Sunayama J, Tsuruta F, Masuyama N, Gotoh Y (2005). JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 170:295 304.
33. Tararuk T, Ostman N, Li W, Björkblom B, Padzik A, Zdrojewska J et al. (2006). JNK1 phosphorylation of SCG10 determines microtubule dynamics and axodendritic length. J Cell Biol 173:265 277.
34. Vermeulen K, Van Bockstaele DR, Berneman ZN (2003). The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36:131 149.
35. Vitale I, Antoccia A, Cenciarelli C, Crateri P, Meschini S, Arancia G et al. (2007). Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis 12:155 166.
36. Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC et al. (1999). Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 274:8208 8216.
37. Weston CR, Davis RJ (2002). The JNK signal transduction pathway. Curr Opin Genet Dev 12:14 21.
38. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ et al. (1994). Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528 1530.